Related Experiment Video
Updated: May 17, 2026
09:40
Isolation, Characterization, And High Throughput Extracellular Flux Analysis of Mouse Primary Renal Tubular Epithelial Cells
Published on: June 20, 2018
HDAC inhibitors in kidney development and disease
Lauren L Brilli1, Lisa M Swanhart, Mark P de Caestecker
1Department of Developmental Biology, University of Pittsburgh, 3501 5th Ave., 5061 BST3, Pittsburgh, PA 15213, USA.
Pediatric Nephrology (Berlin, Germany)
|October 12, 2012
Summary
Histone deacetylase inhibitors (HDACis) show promise for treating kidney injury and disease by reducing damage and fibrosis. Further research is needed to identify specific targets and understand the toxicity of different HDACi classes for therapeutic development.
Area of Science:
- Nephrology
- Pharmacology
- Molecular Biology
Background:
- Histone deacetylase inhibitors (HDACis) demonstrate potential in mitigating acute kidney injury (AKI) and renal fibrosis.
- HDACi treatment induces diverse molecular changes, not solely related to histone acetylation, necessitating target identification.
Purpose of the Study:
- To review the role of HDACis in kidney development, injury, and disease.
- To explore the therapeutic potential and target identification of HDACis in renal contexts.
Main Methods:
- Literature review of studies on HDACis in kidney organogenesis, injury, and disease models.
- Analysis of research focusing on HDACi target identification and toxicity.
Main Results:
- HDACis can attenuate AKI-mediated damage and reduce kidney fibrosis.
- Understanding specific HDACi targets and class-specific toxicities is crucial for therapeutic application.
Conclusions:
- HDACis represent a promising therapeutic avenue for kidney diseases.
- Further investigation into HDACi mechanisms and safety profiles is essential for clinical translation.
Related Concept Videos
01:30Acute Kidney Injury IV: Diagnostic Studies and Prevention
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:25Antihypertensive Drugs: Direct Renin Inhibitors
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
01:25Chronic Kidney Disease I: Introduction
Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
01:28Chronic Kidney Disease III: Interprofessional Care
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
01:22Heart Failure Drugs: Diuretics
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...